COPN logo

Cosmo Pharmaceuticals WBAG:COPN Stock Report

Last Price

€69.50

Market Cap

€1.1b

7D

-1.4%

1Y

n/a

Updated

07 Nov, 2024

Data

Company Financials +

Cosmo Pharmaceuticals N.V.

WBAG:COPN Stock Report

Market Cap: €1.1b

COPN Stock Overview

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends4/6

Cosmo Pharmaceuticals N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cosmo Pharmaceuticals
Historical stock prices
Current Share PriceCHF 69.50
52 Week HighCHF 81.50
52 Week LowCHF 68.50
Beta1.25
11 Month Change-12.58%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-14.20%

Recent News & Updates

Recent updates

Shareholder Returns

COPNAT PharmaceuticalsAT Market
7D-1.4%-3.3%0.2%
1Yn/a6.3%2.2%

Return vs Industry: Insufficient data to determine how COPN performed against the Austrian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how COPN performed against the Austrian Market.

Price Volatility

Is COPN's price volatile compared to industry and market?
COPN volatility
COPN Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement3.4%
10% most volatile stocks in AT Market6.1%
10% least volatile stocks in AT Market1.7%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine COPN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997339Giovanni Di Napoliwww.cosmopharma.com

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis.

Cosmo Pharmaceuticals N.V. Fundamentals Summary

How do Cosmo Pharmaceuticals's earnings and revenue compare to its market cap?
COPN fundamental statistics
Market cap€1.11b
Earnings (TTM)€69.57m
Revenue (TTM)€185.36m

16.0x

P/E Ratio

6.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COPN income statement (TTM)
Revenue€185.36m
Cost of Revenue€43.62m
Gross Profit€141.74m
Other Expenses€72.16m
Earnings€69.57m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)4.34
Gross Margin76.47%
Net Profit Margin37.53%
Debt/Equity Ratio0.1%

How did COPN perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

46%

Payout Ratio